Clovis Oncology マネジメント
マネジメント 基準チェック /34
Clovis Oncologyの CEO はPatrick Mahaffyで、 Apr2009年に任命され、 の在任期間は 14.25年です。 は、会社の株式の0.67%を直接所有しており、その価値は$ 14.56K 。経営陣と取締役会の平均在任期間はそれぞれ7.4年と14.3年です。
主要情報
Patrick Mahaffy
最高経営責任者
n/a
報酬総額
CEO給与比率 | n/a |
CEO在任期間 | 14.3yrs |
CEOの所有権 | 0.7% |
経営陣の平均在職期間 | 7.4yrs |
取締役会の平均在任期間 | 14.3yrs |
経営陣の近況
Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17Recent updates
Clovis Oncology rises on clinical supply agreement with Isotopia
Sep 21Clovis stock rises 15% as Rubraca shows survival benefit as maintenance therapy for ovarian cancer in trial
Sep 12Clovis Oncology: Needs Some Encouraging Data Quickly
Aug 11These Analysts Think Clovis Oncology, Inc.'s (NASDAQ:CLVS) Sales Are Under Threat
Aug 10Clovis Oncology Q2 2022 Earnings Preview
Aug 05EMA recommends restricted use of Clovis cancer drug
Jul 22Clovis Oncology climbs 34% as shareholders reject reverse stock split
Jul 08Clovis: Shifting Toward Nuclear Medicine
Apr 25Clovis Oncology: Forging A Fresh Perspective
Mar 31News Flash: 4 Analysts Think Clovis Oncology, Inc. (NASDAQ:CLVS) Earnings Are Under Threat
Feb 24Buying Beaten Down Clovis Oncology Stock Ahead Of 2022 Catalysts
Jan 11Clovis Oncology Is Now Discounted And Offers A Great Risk-Reward
Dec 30Clovis Oncology Stock: Only Glimmers Of Hope
Oct 07Clovis: Compelling With Upcoming Catalysts
Jul 30Here's Why Shareholders May Want To Be Cautious With Increasing Clovis Oncology, Inc.'s (NASDAQ:CLVS) CEO Pay Packet
Jun 17Clovis Oncology and Inovio gain amid Reddit chatter
Jun 09Clovis Oncology: Another Upcycle Coming
May 08Clovis Oncology drops 7% as Rubraca sales missed estimates amid continued COVID-19 headwinds
May 05Don't Ignore The Fact That This Insider Just Sold Some Shares In Clovis Oncology, Inc. (NASDAQ:CLVS)
Mar 17How Much Did Clovis Oncology's(NASDAQ:CLVS) Shareholders Earn From Share Price Movements Over The Last Three Years?
Feb 22Clovis Oncology: Recent Rally Already Has Me Changing My Game Plan
Jan 31Clovis Oncology: Finally Green Shoots May Be On The Horizon
Jan 29Clovis Oncology reports preliminary Q4 Rubraca revenue between $43.0M to $43.5M
Jan 11What Kind Of Investors Own Most Of Clovis Oncology, Inc. (NASDAQ:CLVS)?
Dec 31Clovis Oncology submits FAP-2286 applications for therapeutic and imaging clinical trial
Dec 29Clovis stock rises as rubraca shows survival benefit in late-stage ovarian cancer study
Dec 21Clovis Oncology existing holder purchases additional $7.5M convertible senior notes
Nov 25Clovis Oncology: Cash Position Is Tight, We Question Management's Guidance
Nov 09Clovis Oncology: Reloading Before And After Q3 Earnings For The Long Term
Nov 06Clovis Oncology EPS beats by $0.11, misses on revenue
Nov 05CEO報酬分析
日付 | 総報酬 | 給与 | 会社業績 |
---|---|---|---|
Sep 30 2022 | n/a | n/a | -US$252m |
Jun 30 2022 | n/a | n/a | -US$263m |
Mar 31 2022 | n/a | n/a | -US$258m |
Dec 31 2021 | US$3m | US$739k | -US$265m |
Sep 30 2021 | n/a | n/a | -US$299m |
Jun 30 2021 | n/a | n/a | -US$310m |
Mar 31 2021 | n/a | n/a | -US$336m |
Dec 31 2020 | US$3m | US$721k | -US$369m |
Sep 30 2020 | n/a | n/a | -US$370m |
Jun 30 2020 | n/a | n/a | -US$385m |
Mar 31 2020 | n/a | n/a | -US$413m |
Dec 31 2019 | US$7m | US$719k | -US$400m |
Sep 30 2019 | n/a | n/a | -US$400m |
Jun 30 2019 | n/a | n/a | -US$396m |
Mar 31 2019 | n/a | n/a | -US$377m |
Dec 31 2018 | US$6m | US$689k | -US$368m |
Sep 30 2018 | n/a | n/a | -US$321m |
Jun 30 2018 | n/a | n/a | -US$291m |
Mar 31 2018 | n/a | n/a | -US$366m |
Dec 31 2017 | US$9m | US$636k | -US$346m |
Sep 30 2017 | n/a | n/a | -US$365m |
Jun 30 2017 | n/a | n/a | -US$370m |
Mar 31 2017 | n/a | n/a | -US$324m |
Dec 31 2016 | US$789k | US$224k | -US$349m |
報酬と市場: Patrickの 総報酬 がUS市場の同規模の企業と比較して妥当かどうかを判断するにはデータが不十分です。
報酬と収益: Patrickの報酬は、過去 1 年間の会社の業績と一致しています。
CEO(最高経営責任者
Patrick Mahaffy (60 yo)
14.3yrs
在職期間
US$2,639,083
報酬
Mr. Patrick J. Mahaffy, M.A., co-founded Clovis Oncology, Inc. in April 20, 2009 and has been its Chief Executive Officer and President since April 20, 2009. Mr. Mahaffy served as the Chief Executive Offic...
リーダーシップ・チーム
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
Executive VP & CFO | 7.3yrs | US$1.19m | 0.072% $ 1.6k | |
Executive VP | 7.5yrs | US$1.20m | 0.068% $ 1.5k | |
Executive VP of Clinical Development & Pharmacovigilance and Chief Medical Officer | 7.9yrs | US$1.24m | 0.078% $ 1.7k | |
Executive VP & Chief Scientific Officer | 3.8yrs | データなし | データなし | |
Executive Vice President of Human Resources | 6.8yrs | データなし | データなし |
7.4yrs
平均在職期間
58yo
平均年齢
経験豊富な経営陣: CLVS.Qの経営陣は経験豊富で経験豊富です(平均在職期間は7.4年)。
取締役
名称 | ポジション | 在職期間 | 報酬 | 所有権 |
---|---|---|---|---|
Co-Founder | 14.3yrs | US$2.64m | 0.67% $ 14.6k | |
Independent Director | 14.3yrs | US$260.00k | 0.041% $ 889.9 | |
Independent Director | 14.5yrs | US$270.00k | 0.040% $ 875.1 | |
Independent Director | 14.5yrs | US$270.00k | 0.17% $ 3.8k | |
Independent Director | 14.5yrs | US$270.00k | 0.044% $ 953.2 | |
Independent Chairman | 10.5yrs | US$287.50k | 0% $ 0 | |
Independent Director | 14.5yrs | US$257.50k | 0.040% $ 872.7 | |
Director | 2yrs | US$375.21k | データなし | |
Independent Director | 10.5yrs | US$259.58k | 0% $ 0 | |
Independent Director | 4.8yrs | US$257.50k | 0% $ 0 | |
Independent Director | 4.8yrs | US$255.00k | 0% $ 0 |
14.3yrs
平均在職期間
67yo
平均年齢
経験豊富なボード: CLVS.Qの 取締役会 は経験豊富で 経験豊富 です ( 14.3年の平均在任期間)。